OFFICE LEASEOffice Lease • February 7th, 2005 • Intarcia Therapeutics, Inc • Pharmaceutical preparations • California
THIS OFFICE LEASE (“Lease”) is made between SPIEKER PROPERTIES, L.P., a California limited partnership (“Landlord”), and BIOMEDICINES INC., a Delaware corporation (“Tenant”), as of February 21, 2001 (the “date of this Lease”).
ATAMESTANE LICENSE AGREEMENTLicense Agreement • February 7th, 2005 • Intarcia Therapeutics, Inc • Pharmaceutical preparations
This agreement (“Agreement”) is made and entered into this 1st day of February 1999 by and between SCHERING AKTIENGESELLSCHAFT, a German corporation, with an address for purposes of this Agreement at Berlin-Wedding, Müllerstralbe 178, Berlin, Germany (“Schering”), and BIOMEDICINES, INC., a Delaware corporation, with an address for purposes of the Agreement at 909 Marina Village Parkway #583, Alameda, California, United States of America (U.S.) 94501 (“BioMedicines”).
CONTRACT RESEARCH AND DEVELOPMENT AGREEMENT ONContract Research and Development Agreement • February 7th, 2005 • Intarcia Therapeutics, Inc • Pharmaceutical preparations
This Contract Research And Development Agreement (“Agreement”) is made effective as of 17 July, 1998 (“Effective Date”), by and among BioMedicines, Inc. (“BioMedicines), a incorporated in the state of Delaware in the United States of America, having its principal business offices at 909 Marina Village Parkway No. 583, Alameda, CA 94501, and Boehringer Ingelheim Pharma KG (“BI Pharma KG”) a German corporation having a place of business at Birkendorfer Strabe 65, 88397 Biberach an der Riss, Federal Republic of Germany.
INTARCIA THERAPEUTICS, INC. INDEMNITY AGREEMENTIndemnity Agreement • February 7th, 2005 • Intarcia Therapeutics, Inc • Pharmaceutical preparations • Delaware
THIS AGREEMENT is made and entered into this day of , 200 by and between INTARCIA THERAPEUTICS, INC., a Delaware corporation (the “Company”), and (“Agent”).
INTERIM DEVELOPMENT AGREEMENTInterim Development Agreement • February 7th, 2005 • Intarcia Therapeutics, Inc • Pharmaceutical preparations • California
This INTERIM DEVELOPMENT AGREEMENT (“Agreement”) is entered into as of this 8th day of November, 2000 between ALZA CORPORATION (“ALZA”) and BIOMEDICINES, INC. (“BioMedicines”).
LICENSE AGREEMENT ENDORECHERCHE Inc. BIOMEDICINES, Inc.License Agreement • February 7th, 2005 • Intarcia Therapeutics, Inc • Pharmaceutical preparations
This agreement (“Agreement”) is made and entered into this 4th of November 2002 by and between Endorecherche Inc, a Canadian corporation (“ERI”), with an address for purposes of the Agreement at 2989, rue de la Promenade Sainte-Foy G1W 2J5, Québec, Canada, and BioMedicines, Inc., a Delaware corporation (“BMI”), with an address for purposes of the Agreement at 2000 Powell Street, Ste 1640, Emeryville, CA, USA, 94608.
SECOND AMENDMENTSecond Amendment • February 7th, 2005 • Intarcia Therapeutics, Inc • Pharmaceutical preparations
THIS SECOND AMENDMENT (the “Amendment”) is made and entered into as of the 26th day of September, 2003, by and between CA-EMERYVILLE PROPERTIES LIMITED PARTNERSHIP, a Delaware limited partnership (“Landlord”), and BIOMEDICINES, INC., a Delaware corporation (“Tenant”).
LICENSE AGREEMENTLicense Agreement • February 7th, 2005 • Intarcia Therapeutics, Inc • Pharmaceutical preparations • California
This LICENSE AGREEMENT executed this 7 day of November, 2002 is made by and between BioMedicines Inc., a Delaware corporation with principal offices located at 2000 Powell Street, Suite 1640, Emeryville, California 94608 (“BioMedicines”) and Chiron Corporation, a Delaware corporation with principal offices located at 4560 Horton Street, Emeryville, California 94608 (“Chiron”).
FIRST AMENDMENT TO LEASELease • February 7th, 2005 • Intarcia Therapeutics, Inc • Pharmaceutical preparations
THIS FIRST AMENDMENT TO LEASE (this “1st Amendment”) is made this 22nd day of March, 2001 between SPIEKER PROPERTIES, L.P., a California limited partnership, (“LANDLORD”), and BIOMEDICINES, INC., a Delaware corporation (“Tenant”).
INTARCIA THERAPEUTICS, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT NOVEMBER 19, 2004Investors’ Rights Agreement • February 7th, 2005 • Intarcia Therapeutics, Inc • Pharmaceutical preparations • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (the “Agreement”) is made as of the 19th day of November, 2004, by and among INTARCIA THERAPEUTICS, INC., a Delaware corporation (the “Company”), the holders of the Company’s Series A Preferred Stock (the “Series A Preferred”), the Company’s Series B Preferred Stock (the “Series B Preferred”), the Company’s Series C Preferred Stock (the “Series C Preferred”) and the Company’s Series D Preferred Stock (the “Series D Preferred”) (hereinafter referred to as the “Prior Investors”) listed on Exhibit A hereto, the purchasers of the Company’s Series E Preferred Stock (the “Purchasers”) listed on Exhibit A hereto, and S. MARK MORAN (“Moran”). The Prior Investors and the Purchasers are referred to hereinafter as the “Investors” and each individually as an “Investor.”
OMEGA INTERFERON LICENSE AGREEMENT EXECUTEDLicense Agreement • February 7th, 2005 • Intarcia Therapeutics, Inc • Pharmaceutical preparations
This agreement (“Agreement”) is made and entered into this July 17, 1998 by and between BOEHRINGER INGELHEIM INTERNATIONAL GMBH, a corporation with offices at D 55216 Ingelheim/Rhein, Germany (“BII”), and BIOMEDICINES, INC., a Delaware corporation, with an address for purposes of the Agreement at 909 Marina Village Parkway #583 Alameda, California, United States of America (U.S.A.) 94501 (“BMI”).
